Verrica Pharmaceuticals Inc. (VRCA) stock
Close on Nov 12, 2026Market cap $63.91MP/E –Yield –
Verrica Pharmaceuticals Inc. grew revenue 106.2% to $30.32M over the twelve months to Jun 30, 2026. Free cash flow was -$17.63M. At the latest close the market valued the company at $63.91M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $63.91M
- P/E ratio
- –
- Price to sales
- 2.11
- Price to book
- 14.84
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $30.32M
- Net income
- -$31.18M
- EPS, diluted
- -$1.67
- Free cash flow
- -$17.63M
- Book value per share
- $0.20
- Diluted shares
- 21M
Trading
- Next earnings
- Nov 13, 2026 (estimated, during market hours)
- Previous close
- $3.91
- Open
- $3.94
- Day's range
- $3.72 – $4.21
- Volume
- 105,819
- Average volume (20 days)
- 63,127
- Beta (5 years)
- 1.08
- 52-week range
- $3.08 – $9.82
- RSI (14 days)
- 50.7
- Volatility (1 year)
- 95.5%
- Relative volume
- 1.71×
- WACC
- 10.3%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | VRCA | S&P 500 | Difference | VRCA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.2% | -2.7% | −4.5 pts | ||
| 3 months | -26.9% | -1.7% | −25.2 pts | ||
| Year to date | -55.2% | +11.9% | −67.1 pts | ||
| 1 year | -2.6% | +12.0% | −14.6 pts | ||
| 3 years | -87.9% | +78.2% | −166.1 pts | -50.5% | +21.2% |
| 5 years | -97.0% | +73.2% | −170.2 pts | -50.4% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Verrica Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- Results
About Verrica Pharmaceuticals
Pharmaceutical Preparations
Verrica Pharmaceuticals is a clinical-stage and commercial therapeutics company focused on developing and commercializing clinician-administered medications for dermatologic diseases and skin cancers. Its primary commercial product is YCANTH, an FDA-approved topical formulation of cantharidin delivered via a single-use precision applicator for treating molluscum contagiosum. The company's development pipeline includes advancing YCANTH for the treatment of common warts, as well as developing VP-315, an investigational injectable peptide therapy for dermatological oncology conditions such as basal cell carcinoma. Its offerings primarily target pediatric dermatologists, general dermatologists, pediatricians, and other primary care health care providers.
Company profile, executives and historyVerrica Pharmaceuticals stock: common questions
What is Verrica Pharmaceuticals's stock price?
VRCA closed at $3.72 on Nov 12, 2026, down 4.86% on the day. Over the past 52 weeks it traded between $3.08 and $9.82.
What is Verrica Pharmaceuticals's market cap?
Verrica Pharmaceuticals was worth $63.91M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is VRCA's P/E ratio?
Verrica Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.67), so it has no meaningful P/E ratio.
How much revenue does Verrica Pharmaceuticals make?
Verrica Pharmaceuticals reported revenue of $30.32M for the twelve months to Jun 30, 2026, up 106.2% from a year earlier.
Does Verrica Pharmaceuticals pay a dividend?
No. Verrica Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Verrica Pharmaceuticals report earnings next?
Verrica Pharmaceuticals is expected to report Q3 FY2026 results on Nov 13, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has VRCA stock performed over the past year?
Including dividends, VRCA returned -2.6% over the past year, against +12.0% for the S&P 500.
Who are Verrica Pharmaceuticals's competitors?
Companies most similar to Verrica Pharmaceuticals by business, industry and size include BFRI, SLGL, VRDN, FBIO, ZNTL.
See a number that looks wrong?